Chiefmaugus stated on his stock twit on July 13 that a major bo is coming. Ask him, but maybe that's why this is so expensive, anticipation of the major bo.
I know plenty. Do you know who invented the compound? I do.
Did you know that your drug uses a toxin as its method of action? And that mine uses a synthetic of the human hormone that produces natural bowel movements?
Not at all saying Linzess is a bad drug. But if you pay attention to the sad refill rate... You'd understand that patients are taking it on an "as needed" basis since the runs are so severe. They wait until they're in so much discomfort before taking the pill. Thats GREAT for Plecanatide, buddy! Being able to stay on the medication means MUCH more revenue down the road. Both drugs clearly have a place in the market. Sadly, mine will do much better.
Perhaps you should do a little reading of your own.
You got it all wrong johnny, Linzess (not Lizness) has the larger share of diarrhea compared to Plecanatide. Do you like the runs johnny? If you're product is so good, why are your earnings per share (-$1.76)? Have you seen your stock lately? It's falling while the IBD has been going up. Probably because of its best in class future competitor Plecanatide's constantly proven pipeline and trials results. Luckily Ironwood only owns about 50% of the Linzess patent, otherwise the losses would be all yours. The only "downstream" issues you'll find are the runs from Linzess. So it seems...
sad to say you have ZERO clue. What makes it a better drug? Stability? Nope - not better. Lower dose required? Nope - it needs around 10x more drug and even then their own data is not convincing. Maybe you need to understand the science behind it. Containing 3 disulfide bonds makes Lizness much more stable and given the immune system relationship to the gut, larger doses of a weaker acting peptide drug (Plecanatide) could cause issues downstream. It may also never be able to help many of the patients afflicted given how quickly this less stable drug would break down. Maybe you need to do some reading on the structure of this peptide versus Lizness, guanylate cyclase activators, and how these drugs actually work so you won't make a fool of yourself with such blanket statements.
If owning all of the drug revenue is the issue, then fine, that is a true statement. But it also means continual dilution and/or an absolute need for a partner to see this through.
And yet they still have the better drug. And increasing institutional ownership. And retain 100% ownership. And will be acquired.
Did I mention they have the better drug?
Pretty funny how they try to avoid saying: we will be out of cash by March. "Net cash used in operating activities was $39.5 million during the six months ended June 30, 2014, as compared to $28.6 million during the six months ended June 30, 2013." Sad to say you only have $50MM +/- left.
Now looking at their numbers: "...Net loss for the three months ended June 30, 2014 was $25.9 million or $0.28 per share, as compared to a net loss of $10 million, or $0.11 per share, for the quarter ended June 30, 2013..."
With 94.1 million common shares issued and outstanding as of June 30, 2014 and a price of $3.55, if they sell 50MM shares thus diluting everyone by 50%, they only raise enough money to get them through 2016 at best.
And don't get me started on the science. The hedge their results at every turn, needing 10-30 times the amount of drug versus Linzess (0.256mg versus 3-9mg of Plecanatide, perhaps even more). Lol....
solid quarter. "profitability for Linzess in sight", so likely will not have to raise more money. And why raise money if you have the option to fire more employees ...
BS - Plecanatide is far less effective. Requires 8x the dose or higher. The statistics on their last info release was poor at best. The big issue is the structure of their drug - less stable than Linzess leading to a more rapid breakdown and the need to use more
My sources have told me this could actually be years away, minimum 2. Lots of upside before that time frame, how soon have you heard?
IRWD owns less than 50% of Linzess. SGYP owns 100% of Plecanatide with a best in class profile. Think about people.
Ineffective management, inefficient use of resources, hopeless pipelines, pathetic profit. Will raise fund or further lay off before you realize.